Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis. Russo V, Fabiani D, Leonardi S, Attena E, et al. J Cardiovasc Pharmacol 2023;81:129-133.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Russo V, Fabiani D, Leonardi S, Attena E, et al. Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis. J Cardiovasc Pharmacol 2023;81:129-133.
PMID: 36607629